[Treatment of Non-Small Cell Lung Cancer with HER2 Alterations]
Toshiaki Takakura1, Nobuyuki Yamamoto
1Internal Medicine Ⅲ , Wakayama Medical University.
Abstract:
HER2 alterations are divided into 3 categories: gene mutation, gene amplification, and protein overexpression. Unlike breast and gastric cancers, where gene amplification and protein overexpression are therapeutic targets, genetic mutations are more likely to be therapeutic targets in NSCLC. There have been few effective treatments for NSCLC with HER2 alterations, but in recent years, TKIs such as pyrotinib and poziotinib, and ADCs such as trastuzumab-deruxtecan(T-Dxd)have shown meaningful anti-tumor efficacy. In particular, T-Dxd received FDA approval in August 2022 for NSCLC patients with certain types of mutations in HER2 gene, and is expected to provide new treatment options in the future.
Insights
HER2 alterations in non-small cell lung cancer (NSCLC) are increasingly targeted by therapies. Trastuzumab-deruxtecan (T-Dxd) shows significant efficacy for specific HER2 mutations, offering new treatment options.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- HER2 alterations in non-small cell lung cancer (NSCLC) present unique therapeutic challenges compared to breast and gastric cancers.
- While gene amplification and protein overexpression are targets in other cancers, HER2 mutations are key in NSCLC.
- Historically, effective treatments for HER2-altered NSCLC were limited.
Purpose:
- To review the landscape of HER2 alterations in NSCLC.
- To highlight emerging targeted therapies and their efficacy.
- To discuss the impact of recent approvals on treatment strategies.
Summary:
- HER2 alterations in NSCLC are categorized into gene mutation, amplification, and overexpression.
- Unlike other cancers, HER2 mutations are the primary therapeutic focus in NSCLC.
- Tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) like trastuzumab-deruxtecan (T-Dxd) demonstrate significant anti-tumor activity.
- T-Dxd received FDA approval in August 2022 for specific HER2 mutations in NSCLC, representing a breakthrough.
Impact:
- T-Dxd approval provides a crucial new therapeutic option for NSCLC patients with HER2 mutations.
- This advancement signifies progress in precision medicine for a previously difficult-to-treat cancer subset.
- Further research into HER2-targeted therapies is warranted to improve patient outcomes.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...